| Pharmacokinetic parameters |
Control phase |
Treatment phase |
Geometric mean ratio |
90% CI |
| Cmax(ng/mL) |
415.08 ± 67.63 |
685.58 ± 184.24* |
1.61 |
1.38-1.88 |
| Tmax(h) |
2.37 ± 0.37 |
2.41 ± 0.36 |
1.02 |
0.94-1.10 |
| Ke (h-1) |
0.088 ± 0.02 |
0.087 ± 0.02 |
0.99 |
0.87-1.12 |
| T1/2 (h) |
8.27 ± 1.82 |
8.48 ± 2.15 |
1.01 |
0.91-1.14 |
| AUClast(ng.h/mL) |
2520.92 ± 516.92 |
4454.48 ± 1238.27* |
1.74 |
1.53-1.98 |
| AUCinf (ng.h/mL) |
2541.65 ± 527.18 |
4512.33 ± 1265.17* |
1.75 |
1.54-1.99 |
| CL/F (L/h) |
49.46 ± 12.27 |
28.37 ± 7.03* |
0.56 |
0.50-0.64 |
| Vd/F (L) |
591.73 ± 197.25 |
342.62 ± 108.56* |
0.58 |
0.48-0.69 |
Pharmacokinetic data are expressed as mean ± SD. *P < 0.05, compared with the control phase. |
